ArticleBMC cardiovascular disorders2025
Long-term safety and efficacy of ivabradine after direct percutaneous coronary intervention in patients with acute myocardial infarction complicated by heart failure: a single-center retrospective study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A novel electrochemical sensor based on Al-doped ZnO nanoparticles-modified carbon paste electrode for ivabradine sensitive monitoring in human plasma.Analytical and bioanalytical chemistry · 2026Article
- Ivabradine in acute care: Revisiting the funny current in critical care context.World journal of critical care medicine · 2025Review
- Heart rate management using ivabradine in acute myocardial infarction: a propensity score-matched single-center study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThere are few studies on the long-term efficacy and safety of ivabradine in patients with acute myocardial infarction (AMI) complicated by heart failure. We aimed to assess the above questions and provide clinical experience.
methodsThe study enrolled patients with AMI complicated by heart failure who underwent percutaneous coronary intervention (PCI) from January 2022 to June 2023. Based on the discharge medications, patients were stratified into two groups: (1) the ivabradine group (receiving ivabradine with or without β-blockers) and (2) the β-blocker monotherapy group (control). Efficacy effects included in-hospital heart rate control, all-cause mortality, and heart failure readmission. Safety effects comprised recurrent myocardial infarction and recurrent angina rehospitalization. The initial cohort comprised 517 patients, excluding 62 who discontinued ivabradine, leaving 455 for analysis (ivabradine group: n = 101; β-blocker group: n = 354). Following 1:1 propensity score matching (PSM), 92 matched pairs were available for analysis. Potential confounding variables were adjusted through robust Cox proportional hazards regression modeling.
resultsPost-treatment, heart rate at discharge significantly decreased in both groups, with the ivabradine group demonstrating lower values than the β-blocker group (P < 0.05). At 2-year follow-up (post- PSM), the ivabradine group showed a reduced risk of heart failure readmission compared to the β-blocker group (hazard ratio [HR]: 0.32; 95% confidence interval [CI]: 0.13-0.77; P = 0.012). However, no significant intergroup difference was observed in all-cause mortality (HR: 1.04; 95% CI: 0.41-2.61; P = 0.937). No significant differences were observed between the two groups in the safety endpoints, including recurrent myocardial infarction or rehospitalization for angina.
conclusionEarly administration of ivabradine following PCI in patients with AMI complicated by heart failure can lower resting heart rate and is beneficial in reducing the risk of rehospitalization for heart failure. However, these findings support further investigation in future large prospective studies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.